DENTSPLY SIRONA Inc.
Rating
Updated: Aug 21, 2026Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
DENTSPLY SIRONA Inc. develops, manufactures, and markets dental equipment supported by cloud-enabled solutions, dental products, and healthcare consumable products in urology and enterology worldwide....
Latest News
4 days ago · zacks.com
Reasons to Retain DENTSPLY SIRONA Stock in Your Portfolio for NowXRAY's digital dentistry, R&D and restructuring support growth, but CAD/CAM, implants, SureSmile and tariff pressures pose near-term risks.
14 days ago · zacks.com
XRAY's Q2 Earnings Beat Meets Steady Guidance and Margin PressureXRAY beat Q2 earnings and revenue estimates, held 2026 guidance and improved cash flow, but falling sales and margin pressure cloud the recovery.
15 days ago · prnewswire.com
Did Dentsply Sirona Inc. Insiders Breach their Fiduciary Duties to Shareholders?Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
1 month ago · prnewswire.com
New At-Home Surity™ Urinary Management System Designed to Provide Comfort and Reliable Care for People Living with Urinary IncontinenceNew system completes the Surity™ portfolio of external catheters for both men and women Integrates into daily routines to help support management of urinary incontinence at home Designed to operate quietly overnight, new Surity™ System helps minimize nighttime interruptions to support comfort and rest MÖLNDAL, Sweden, Aug. 19, 2026 /PRNewswire/ -- Wellspect HealthCare today announced the U.S. launch of the Surity™ Urinary Management System, a discreet at-home urine collection device designed to support people living with urinary incontinence and those who help care for them. This completes the full Surity™ portfolio in the U.S., following the introduction of the Surity™ Female and Male External Catheters earlier this year.
2 months ago · marketbeat.com
DENTSPLY SIRONA Q2 Earnings Call HighlightsDENTSPLY SIRONA NASDAQ: XRAY reported second-quarter 2026 revenue of $898 million, down 4.1% on a reported basis and 6.3% on a constant-currency basis, as the dental products company continued its turnaround plan amid lower volumes in several businesses and distributor inventory reductions in Europe.
2 months ago · zacks.com
XRAY Stock Falls Despite Q2 Earnings Beat, Wellspect Drives SalesDENTSPLY SIRONA's Q2 sales fall 4.1% as dental weakness offsets Wellspect growth, while margins improve and 2026 guidance is maintained.
2 months ago · zacks.com
Here's What Key Metrics Tell Us About Dentsply (XRAY) Q2 EarningsThe headline numbers for Dentsply (XRAY) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
2 months ago · seekingalpha.com
DENTSPLY SIRONA Inc. (XRAY) Q2 2026 Earnings Call TranscriptDENTSPLY SIRONA Inc. (XRAY) Q2 2026 Earnings Call Transcript
2 months ago · zacks.com
Dentsply International (XRAY) Beats Q2 Earnings and Revenue EstimatesDentsply International (XRAY) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of $0.36 per share. This compares to earnings of $0.52 per share a year ago.
2 months ago · zacks.com
DENTSPLY SIRONA to Post Q2 Earnings: What's in Store for the Stock?XRAY's Q2 results are likely to reflect transformation investments, dealer inventory cuts and weak implants, while Wellspect growth offers support.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove XRAY